JP Morgan Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $27
Guggenheim Maintains Buy on Monte Rosa Therapeutics, Lowers Price Target to $28
Wells Fargo Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $27
Monte Rosa Therapeutics (NASDAQ:GLUE) Beats Q2 Revenue Estimates but Posts Wider Loss
Monte Rosa Therapeutics Q2 EPS $(0.43) Misses $(0.38) Estimate, Sales $8.968M Beat $5.524M Estimate
Wedbush Maintains Outperform on Monte Rosa Therapeutics, Lowers Price Target to $27
Guggenheim Maintains Buy on Monte Rosa Therapeutics, Raises Price Target to $35
JP Morgan Maintains Overweight on Monte Rosa Therapeutics, Raises Price Target to $31
Monte Rosa Therapeutics Inc (NASDAQ:GLUE) Reports Q1 2026 Results as Clinical Progress Drives Focus on Upcoming Catalysts
Monte Rosa Therapeutics Q1 EPS $(0.45) Misses $(0.37) Estimate, Sales $4.210M Miss $10.883M Estimate
Monte Rosa Therapeutics, Inc. (GLUE) Presents at AACR Annual Meeting 2026 - Slideshow
Monte Rosa To Present Preclinical Data Highlighting Potential Of CCNE1-Directed MGD, MRT-55811, To Treat CCNE1-Amplified Solid Tumors At AACR Annual Meeting 2026
Guggenheim Maintains Buy on Monte Rosa Therapeutics, Lowers Price Target to $30
Wells Fargo Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $29
Monte Rosa Therapeutics Q4 EPS $(0.55) Misses $(0.33) Estimate, Sales $2.781M Miss $15.506M Estimate
Monte Rosa Highlights Updated Phase 1/2 Data Showing 67% Overall RECIST Disease Control And Tumor Reductions In Heavily Pretreated mCRPC
Monte Rosa Therapeutics Files Prospectus For Offering Mixed Shelf; Terms Not Disclosed
Piper Sandler Reiterates Overweight on Monte Rosa Therapeutics, Raises Price Target to $37
Reported Earlier, Monte Rosa Therapeutics Prices $300M Underwritten Public Offering Of 11.125M Shares At $24.00 And 1.375M Pre-Funded Warrants
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.